This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Tekmira Provides Corporate Update And Announces Second Quarter 2012 Results

Tekmira Reports New Interim Clinical Data From TKM-PLK1 Oncology Phase 1 Clinical Trial

Conference Call at 4:30 pm Eastern Time Today

VANCOUVER, B.C., Aug. 14, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today its financial and operating results for the second quarter ended June 30, 2012 and provided a corporate update.

"Over the past few months, significant clinical data have been reported providing further validation that Tekmira's LNP technology is the 'gold standard' and most widely-used delivery technology in the RNAi field. Building on this momentum, we are releasing interim TKM-PLK1 results demonstrating that TKM-PLK1 is showing promising signs of drug activity in an ongoing Phase 1 human clinical trial," said Dr. Mark J. Murray, Tekmira's President and CEO.

"We believe Tekmira is entering the second half of the year in a solid position, bolstered by positive RNAi clinical data and the recent news that Talon was granted accelerated approval for Marqibo, which triggered a milestone payment to Tekmira. The Court's decision in July to deny Alnylam and AlCana's requests to file motions for summary judgment means that the ongoing litigation will proceed to trial on all counts this fall – and all issues will be decided by a jury," added Dr. Murray.

TKM-PLK1 Phase 1 Clinical Data

"We are very encouraged with the interim results from our ongoing Phase 1 human clinical trial for TKM-PLK1 in an advanced and heavily pre-treated population of cancer patients with solid tumors. TKM-PLK1 is being dosed on an aggressive once weekly protocol and the drug has been generally well tolerated. In addition, we have seen encouraging signs of drug activity with one patient achieving a 63% reduction in tumor burden (partial response) and who remains on study after receiving 15 doses of drug over 5 months, and another patient achieving stable disease who received 18 doses of TKM-PLK1 over 6 months," added Dr. Murray.

1 of 9

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,915.07 -70.54 -0.42%
S&P 500 1,964.68 -8.15 -0.41%
NASDAQ 4,396.2040 -22.83 -0.52%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs